drugset / Trial / NCT03489343
Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This was the first study to test Sym023 in humans. The primary purpose of this study was to see if Sym023 is safe and tolerable for patients with locally advanced/unresectable or metastatic solid tumor malignancies or lymphomas that are refractory to available therapy or for which no standard therapy is available.
Timeline
- Start
- 2018-05-24
- Primary completion
- 2020-06-03
- Completion
- 2020-06-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sym023 | Monoclonal antibody | 0.03 mg/kg | Intravenous |
| Subject | Sym023 | Monoclonal antibody | 0.1 mg/kg | Intravenous |
| Subject | Sym023 | Monoclonal antibody | 0.3 mg/kg | Intravenous |
| Subject | Sym023 | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | Sym023 | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | Sym023 | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Sym023 | Monoclonal antibody | 20 mg/kg | Intravenous |